Tarsus Pharma Q1 revenue jumps on XDEMVY sales

Tarsus Pharmaceuticals

06/05/2026 21:31

Overview

U.S. eye care drugmaker's Q1 revenue rose over 85% yr/yr but missed analyst expectations

Net loss narrowed from prior year as higher sales offset increased expenses

Company reaffirmed 2026 XDEMVY sales guidance and noted China milestone payment

Outlook

Tarsus reaffirms 2026 guidance of $670-700 mln XDEMVY net product sales

Company expects XDEMVY peak sales potential to exceed $2 bln

Topline data from TP-05 Phase 2 trials expected in first half of 2027

Result Drivers

XDEMVY SALES GROWTH - Co said revenue growth was driven by increased prescribing by eye care professionals and broader patient screening

DIRECT-TO-CONSUMER CAMPAIGN - Co said DTC campaign boosted patient demand and engagement, increasing high-value actions on XDEMVY.com by about 40% quarter-over-quarter

CHINA MILESTONE PAYMENT - Co recorded $15 mln regulatory milestone payment from Greater China partner after XDEMVY approval

Company press release: ID:nGNX3rJ4fW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$162.05 mln
$148.42 mln (8 Analysts)
Q1 EPS
-$0.16
Q1 Net Income
-$6.97 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Tarsus Pharmaceuticals Inc is $92.50, about 42.2% above its May 5 closing price of $65.04

The stock recently traded at 96 times the next 12-month earnings vs. a P/E of 36 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)